文献速递神经肿瘤

血液中的miR-497与219有助于脑膜瘤分类

miR-497 and 219 in blood aid meningioma classification.
PubMed 文献 · J Neurooncol · 2022-09-08

研究检测74例脑膜瘤样本(WHO I级25例、II级25例、III级24例)和53例健康对照的血清及外泌体miR-497,并在56例脑膜瘤样本(WHO I级22例、II级14例、III级20例)检测血清miR-219,采用qPCR定量。结果显示血清和外泌体miR-497可区分脑膜瘤与对照,且miR-497适用于脑膜瘤分级;联合miR-497与miR-219在脑膜瘤分类中的效能高于两者单独使用,两者均随脑膜瘤甲基化类别呈现明显变化。

要点

  • 血清和外泌体miR-497可区分脑膜瘤与健康对照。
  • miR-497是脑膜瘤分级的合适标志物。
  • 联合miR-497与miR-219分类效能高于两者单独使用。

核心结论

  • 血清miR-497是脑膜瘤诊断和分类的有效且易测量的生物标志物。
  • 联合miR-497与miR-219在脑膜瘤分类中显示更高的准确度。
  • 本研究首次评估血清循环miRNA与脑膜瘤甲基化状态的相关性。

研究设计与样本

  • 研究检测74例脑膜瘤样本(WHO I级25例、II级25例、III级24例)和53例健康对照的血清及外泌体miR-497水平。
  • 研究检测56例脑膜瘤样本(WHO I级22例、II级14例、III级20例)的血清miR-219水平。
  • 采用qPCR进行miRNA定量,并测试内源性及外源性两种归一化方法对miR-497诊断价值的影响。

主要发现

  • 血清和外泌体miR-497水平可区分脑膜瘤样本与对照样本。
  • miR-497是脑膜瘤分级的合适识别标志物。
  • 联合miR-497与miR-219在脑膜瘤分类中的效能高于miR-497或miR-219单独使用。
  • miR-497和miR-219均随脑膜瘤甲基化类别呈现明显变化。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The current WHO classification and methylation status help predict meningioma recurrence and prognosis. However, up to date, there is no circulating biomarker showing clinical value in meningioma diagnosis or classification. Circulating miRNAs showed the potential to be used as cancer biomarkers in various tumours. This research evaluated specific miRNAs, miR-497 and miR-219, as convenient and efficient predictors of meningioma grades. METHODS: We studied serum and exosomal levels of miR-497 in 74 meningioma samples (WHO grade I = 25, WHO grade II = 25, and WHO grade III = 24) and 53 healthy controls. The serum level of miR-219 was studied in 56 meningioma samples WHO grade I = 22, WHO grade II = 14, and WHO grade III = 20). We used qPCR for miRNA quantification. We also tested two different normalisers, endogenous and external, and evaluated their impact on the diagnostic value of miR-497. RESULTS: The serum and exosomal levels of miR-497 distinguished meningioma from the control samples. Moreover, miR-497 was a suitable identifier for meningioma grade. When we combined miR-497 and miR-219, the efficacy of the combined biomarker was higher than miR-497 or miR-219 when used individually in meningioma classification. Both miR-497 and miR-219 showed a noticeable change with the methylation class of meningioma. CONCLUSION: This study shows that serum miR-497 is an effective and easy-to-measure biomarker for meningioma diagnosis and classification. Moreover, when we combined miR-497 and miR-219, the combined biomarker showed enhanced accuracy in meningioma classification. Furthermore, this is the first study to evaluate the correlation between serum circulating miRNA and the methylation status in meningioma.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Abdelrahman A, Negroni C, Sahm F, et al. miR-497 and 219 in blood aid meningioma classification. J Neurooncol. 2022. PMID: 36076132. doi:10.1007/s11060-022-04126-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。